Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters

Reuters

2025/06/12

Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters

Teleflex Inc. $(TFX)$, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542451871"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542451871\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542451871?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542451871","market":"nz","top_or_hot":-1,"title":"Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teleflex Inc. <a href=\"https://laohu8.com/S/TFX\">$(TFX)$</a>, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-12 18:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teleflex Inc. <a href=\"https://laohu8.com/S/TFX\">$(TFX)$</a>, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"納斯達克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL8HjHww:1","article_id":"2542451871","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542451871","pubTimestamp":1749724213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow Chlorhexidine-Impregnated Central Venous Catheters. Teleflex Inc. , a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow Chlorhexidine-Impregnated Central Venous Catheters . The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections  in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue and Arrowg+ard Blue Plus CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","TFX":"泰利福"},"translate_title":"Teleflex Inc.宣布新研究表明Arrow™氯己定浸渍中心静脉导管的感染率降低70.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TFX":0.9},"content_text":"Teleflex Inc. Announces New Study Demonstrating 70.5% Reduction in Infection Rates with Arrow™ Chlorhexidine-Impregnated Central Venous Catheters\n    \n\n        Teleflex Inc. $(TFX)$, a global provider of medical technologies, announced findings from a new multinational study evaluating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). The prospective cohort study included over 6,670 patients from intensive care units across eight hospitals in India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey. The study demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) in patients using the impregnated CVCs, compared to those with unprotected CVCs. This research supports the effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The full results have been published and are accessible in the journal ScienceDirect.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466436-en) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}